Mixed Treatment Comparison and Bayesian Integrated Economic Evaluation of Cost-Effectiveness and Budget Impact of TNF-alpha inhibitors for Rheumatoid Arthritis after Failure of Conventional DMARD Therapy (notice n° 689323)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05015cam a2200325 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121205636.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Launois, Robert |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Mixed Treatment Comparison and Bayesian Integrated Economic Evaluation of Cost-Effectiveness and Budget Impact of TNF-alpha inhibitors for Rheumatoid Arthritis after Failure of Conventional DMARD Therapy |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2016.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 44 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Contexte : 80% des patients souffrant de polyarthrite rhumatoïde ne répondent pas aux traitements à base de méthotrexate et font l’objet d’une prise en charge par anti TNF-α. Objectifs : Cette étude se propose d’évaluer l’efficacité et l’innocuité des biothérapies utilisées en seconde ligne de traitement sur les patients atteints de polyarthrite rhumatoïde modérée ou sévère dont la réponse aux traitements conventionnels est inadéquate, d’estimer leur efficience respective et d’estimer l’impact budgétaire des traitements mis en œuvre. Méthode : Une revue systématique de la littérature disponible entre 1999 et 2013 a été faites en respectant les recommandations Prisma. La synthèse quantitative des résultats publiés dans les essais randomisés retenus a fait l’objet d’une méta-analyse en réseau. Un modèle de Markov a été développé pour retracer l’évolution de la pathologie sous traitement et le parcours de soins des malades. Les consommations de biens et services médicaux ont été extraites d’une étude observationnelle dont les résultats ont alimenté l’analyse cout efficacité et le modèle d’impact budgétaire. Résultat : La méta-analyse montre des différences significatives sur le critère ACR 20 des biothérapies par rapport au méthotrexate mais aucune différence significative entre les biothérapies sur la base de ce même critère. L’analyse cout efficacité révèle que l’adalimumab se situe sur la frontière des meilleurs traitements financièrement acceptables en deçà du seuil de 1,715 € et qu’au-delà, c’est l’etanercept qui est le meilleur traitement. Le modèle d’impact budgétaire montre que le remplacement de l’etanercept par des molécules plus onéreuse et moins efficace couterait à la collectivité 28 millions d’euros en cinq ans. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Méta analyse en réseau et évaluation de l’efficience des traitements de la polyarthrite rhumatoïde par anti TNF-alpha utilisant un modèle bayésien intégré Background: Eighteen percent of patients with rheumatoid arthritis (RA) do not respond adequately to conventional treatment with Methotrexate, upon which biological agents known as TNF-α inhibitors may be used. Objectives: Our objective was three-fold: first, to assess the efficacy and safety of second line biotherapies on a patient population presenting moderate to severe RA and who were unsuccessfully treated with conventional DMARDs, second, to evaluate the cost-effectiveness of different RA therapeutic strategies, and third, to estimate the budget impact of RA management in France. Method: We conducted a systematic review of randomized control trials, conducted between 1999 and 2010, targeting RA patients undergoing treatment with a biological agent, as well as a quantitative synthesis using a mixed treatment comparison approach. A Markov model was built to reproduce RA patients’ care trajectories within the French healthcare system. Data on resource consumption were collected from an observational study and used to as model parameters in order to assess the cost-effectiveness and budget impact of biotherapies available in France. Results: Our analysis revealed significant differences between biotherapies and DMARDs, in terms of ACR50 response. When considering a willingness-to-pay (WTP) of €1,715, adalimumab was the most efficient treatment within, and etanercept the most effective beyond this threshold. The Budget Impact Analysis (BIA) showed that a decision to replace etanercept with more expensive and less effective therapies could result in a €28 million loss over 5 years. Conclusion: As cost-effective second-line treatments in RA management, adalimumab and etanercept should constitute the preferred therapeutic options in France. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | analyse d’impact budgétaire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | polyarthrite rhumatoïde |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | bénéfice monétaire net |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | méta-analyse en réseau |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anti-TNF-α |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | TNF-alpha inhibitors |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | markov model |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | budget impact |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mixed treatment comparison |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cost-effectiveness |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | rheumatoid arthritis |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Moine, Jean-Gabriel |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Huynh, TMT |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Journal de gestion et d'économie médicales | 34 | 2 | 2016-12-20 | p. 145-160 | 2262-5305 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-journal-de-gestion-et-d-economie-medicales-2016-2-page-145?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-journal-de-gestion-et-d-economie-medicales-2016-2-page-145?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux